Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab ; volume:150 ; number:10 ; day:18 ; month:10 ; year:2024 ; pages:1-12 ; date:10.2024
Journal of cancer research and clinical oncology ; 150, Heft 10 (18.10.2024), 1-12, 10.2024
- Creator
-
Wang, Dayang
Zhang, Jiubing
Bu, Chaojie
Liu, Guanzheng
Guo, Guangzhong
Zhang, Ziyue
Lv, Guangming
Sheng, Zhiyuan
Yan, Zhaoyue
Gao, Yvshuai
Wang, Meiyun
Liu, Gang
Zhao, Ruijiao
Li, Tianxiao
Ma, Chunxiao
Bu, Xingyao
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00432-024-05997-8
- URN
-
urn:nbn:de:101:1-2501232120475.132070989020
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wang, Dayang
- Zhang, Jiubing
- Bu, Chaojie
- Liu, Guanzheng
- Guo, Guangzhong
- Zhang, Ziyue
- Lv, Guangming
- Sheng, Zhiyuan
- Yan, Zhaoyue
- Gao, Yvshuai
- Wang, Meiyun
- Liu, Gang
- Zhao, Ruijiao
- Li, Tianxiao
- Ma, Chunxiao
- Bu, Xingyao
- SpringerLink (Online service)
Other Objects (12)
Bevacizumab for patients with recurrent multifocal glioblastomas
Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas
Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis
Quantitative T1 mapping indicates tumor infiltration beyond the enhancing part of glioblastomas
Tumor cell response to bevacizumab single agent therapy in vitro
Tumor cell response to bevacizumab single agent therapy in vitro
Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication
Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report
Survival Analysis in Elderly Patients with Glioblastomas: The Influence of Clinical Status, Tumor and Surgical Features
Tumor-associated epilepsy in patients with brain metastases: necrosis-to-tumor ratio forecasts postoperative seizure freedom
Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
Dosimetric impact of tumor treating field (TTField) transducer arrays onto treatment plans for glioblastomas – a planning study
Bevacizumab for patients with recurrent multifocal glioblastomas
Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas
Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis
Quantitative T1 mapping indicates tumor infiltration beyond the enhancing part of glioblastomas
Tumor cell response to bevacizumab single agent therapy in vitro
Tumor cell response to bevacizumab single agent therapy in vitro
Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication
Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report
Survival Analysis in Elderly Patients with Glioblastomas: The Influence of Clinical Status, Tumor and Surgical Features
Tumor-associated epilepsy in patients with brain metastases: necrosis-to-tumor ratio forecasts postoperative seizure freedom
Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
Dosimetric impact of tumor treating field (TTField) transducer arrays onto treatment plans for glioblastomas – a planning study
Bevacizumab for patients with recurrent multifocal glioblastomas
Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas
Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis
Quantitative T1 mapping indicates tumor infiltration beyond the enhancing part of glioblastomas
Tumor cell response to bevacizumab single agent therapy in vitro
Tumor cell response to bevacizumab single agent therapy in vitro
Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication
Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report
Survival Analysis in Elderly Patients with Glioblastomas: The Influence of Clinical Status, Tumor and Surgical Features
Tumor-associated epilepsy in patients with brain metastases: necrosis-to-tumor ratio forecasts postoperative seizure freedom
Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection